Drug intelligence / Profile preview

ABD-004

Development stage: Unknown
Lead developer: Abdera Therapeutics
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ABD-004 is a therapeutic radiopharmaceutical in early-stage development for the treatment of neoplasms (cancers). It is being developed by Abdera Therapeutics. As a radiopharmaceutical, it likely functions by delivering targeted radiation to cancer cells, though specific molecular targets and mechanisms of action have not been disclosed publicly. The drug is currently at the discovery stage and has not yet entered clinical trials or received regulatory approval[1].

Beyond the preview

Go deeper on ABD-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABD-004.

Explore the full profile